<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a case of therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> after low-dosed <z:chebi fb="0" ids="50750">topoisomerase II inhibitor</z:chebi> (<z:chebi fb="0" ids="4911">etoposide</z:chebi>) treatment for <z:e sem="disease" ids="C0024291" disease_type="Disease or Syndrome" abbrv="">hemophagocytic lymphohistiocytosis</z:e> (HLH) </plain></SENT>
<SENT sid="1" pm="."><plain>A 62-yr-old female patient had previously been treated with a HLH-94 protocol containing a low-dose of <z:chebi fb="0" ids="4911">etoposide</z:chebi> (total dose of 300 mg/m2) </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-one months later, the patient was admitted to the hematology department with general <z:mp ids='MP_0000746'>weakness</z:mp> and upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>Peripheral blood smear and bone marrow study revealed <z:hpo ids='HP_0004845'>acute monocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>There was no evidence of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and a cytogenetic study showed no chromosomal abnormalities </plain></SENT>
</text></document>